FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212868879> ?p ?o ?g. }

• W4212868879 endingPage "138" @default.
• W4212868879 startingPage "124" @default.
• W4212868879 abstract "Nerve-sparing radical prostatectomy (NSRP) had to be performed because approximately 94% of patients are diagnosed with localized prostate cancer (PCa). Although NSRP is generally done to improve functional outcomes, erectile dysfunction (ED) is one of the most prevailing complications after radical prostatectomy (RP). Phosphodiesterase type 5 inhibitors (PDE5-Is) are the most well-known treatment agent for postoperative ED. This study aimed to assess the efficacy of PDE5-Is in patients with ED after NSRP.In this systematic literature review, randomized controlled trials on the efficacy and safety of PDE5-Is in patients who underwent NSRP were searched in MEDLINE, EMBASE, and the Cochrane Controlled Trials Register using the OVID platform. This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane Review Methods. The quality of the evidence of the outcome data was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.A total of 14 trials involving 2,822 patients were included. Significant improvements in the International Index of Erectile Function-Erectile Function (IIEF) domain score [mean difference (MD) =4.93; 95% confidence interval (CI): 4.14-5.71; P<0.00001] and erectile function recovery events [odds ratio (OR) =2.06; 95% CI: 1.45-2.94; P<0.0001] were observed after PDE5-I treatment. A higher positive response to Sexual Encounter Profile (SEP) question 2 (OR =2.27; 95% CI: 1.80-2.86; P<0.00001) and question 3 (OR =2.78; 95% CI: 1.97-3.91; P<0.00001) was also found after PDE5-I treatment. However, the incidence of treatment-emergent adverse events (TEAEs) was higher after PDE5-I treatment than after placebo treatment (OR =2.91; 95% CI: 1.84-4.61). Furthermore, the incidence of headache (OR =3.38; 95% CI: 2.40-4.75) and flushing (OR =9.44; 95% CI: 4.30-20.70) was also significantly higher after PDE5-I treatment (P<0.00001). In terms of the quality of the evidence of the outcome data, inconsistency problems were detected in all outcomes and imprecision problems in most outcomes.PDE5-I treatment was more effective to placebo treatment in patients with ED after NSRP. No clinically serious complications were found in spite of the incidence of TEAEs being higher after PDE5-I treatment." @default.
• W4212868879 created "2022-02-24" @default.
• W4212868879 creator A5010592525 @default.
• W4212868879 creator A5021448271 @default.
• W4212868879 creator A5025457755 @default.
• W4212868879 creator A5052489990 @default.
• W4212868879 creator A5073414190 @default.
• W4212868879 date "2022-02-01" @default.
• W4212868879 modified "2023-09-30" @default.
• W4212868879 title "Efficacy of phosphodiesterase type 5 inhibitors in patients with erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis" @default.
• W4212868879 cites W1275039145 @default.
• W4212868879 cites W1559144087 @default.
• W4212868879 cites W156230426 @default.
• W4212868879 cites W1975503171 @default.
• W4212868879 cites W1978545009 @default.
• W4212868879 cites W1984429089 @default.
• W4212868879 cites W1987026657 @default.
• W4212868879 cites W1990875217 @default.
• W4212868879 cites W1997858761 @default.
• W4212868879 cites W2010043799 @default.
• W4212868879 cites W2014704844 @default.
• W4212868879 cites W2014737064 @default.
• W4212868879 cites W2020389062 @default.
• W4212868879 cites W2024833183 @default.
• W4212868879 cites W2028322409 @default.
• W4212868879 cites W2031931231 @default.
• W4212868879 cites W2036750965 @default.
• W4212868879 cites W2040774455 @default.
• W4212868879 cites W2041626476 @default.
• W4212868879 cites W2055125592 @default.
• W4212868879 cites W2070010226 @default.
• W4212868879 cites W2080869786 @default.
• W4212868879 cites W2081966172 @default.
• W4212868879 cites W2094457083 @default.
• W4212868879 cites W2095279301 @default.
• W4212868879 cites W2099702762 @default.
• W4212868879 cites W2115483503 @default.
• W4212868879 cites W2122960977 @default.
• W4212868879 cites W2124424098 @default.
• W4212868879 cites W2125435699 @default.
• W4212868879 cites W2140847299 @default.
• W4212868879 cites W2144406289 @default.
• W4212868879 cites W2146822966 @default.
• W4212868879 cites W2147232111 @default.
• W4212868879 cites W2158072358 @default.
• W4212868879 cites W2169961966 @default.
• W4212868879 cites W2171081137 @default.
• W4212868879 cites W2219978888 @default.
• W4212868879 cites W22857079 @default.
• W4212868879 cites W2421009060 @default.
• W4212868879 cites W2516622266 @default.
• W4212868879 cites W2588302396 @default.
• W4212868879 cites W2744564831 @default.
• W4212868879 cites W66622570 @default.
• W4212868879 doi "https://doi.org/10.21037/tau-21-881" @default.
• W4212868879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35280664" @default.
• W4212868879 hasPublicationYear "2022" @default.
• W4212868879 type Work @default.
• W4212868879 citedByCount "2" @default.
• W4212868879 countsByYear W42128688792023 @default.
• W4212868879 crossrefType "journal-article" @default.
• W4212868879 hasAuthorship W4212868879A5010592525 @default.
• W4212868879 hasAuthorship W4212868879A5021448271 @default.
• W4212868879 hasAuthorship W4212868879A5025457755 @default.
• W4212868879 hasAuthorship W4212868879A5052489990 @default.
• W4212868879 hasAuthorship W4212868879A5073414190 @default.
• W4212868879 hasBestOaLocation W42128688791 @default.
• W4212868879 hasConcept C121608353 @default.
• W4212868879 hasConcept C126322002 @default.
• W4212868879 hasConcept C126894567 @default.
• W4212868879 hasConcept C156957248 @default.
• W4212868879 hasConcept C168563851 @default.
• W4212868879 hasConcept C2776478404 @default.
• W4212868879 hasConcept C2779466945 @default.
• W4212868879 hasConcept C2779929075 @default.
• W4212868879 hasConcept C2780192828 @default.
• W4212868879 hasConcept C44249647 @default.
• W4212868879 hasConcept C71924100 @default.
• W4212868879 hasConcept C74534348 @default.
• W4212868879 hasConcept C95190672 @default.
• W4212868879 hasConceptScore W4212868879C121608353 @default.
• W4212868879 hasConceptScore W4212868879C126322002 @default.
• W4212868879 hasConceptScore W4212868879C126894567 @default.
• W4212868879 hasConceptScore W4212868879C156957248 @default.
• W4212868879 hasConceptScore W4212868879C168563851 @default.
• W4212868879 hasConceptScore W4212868879C2776478404 @default.
• W4212868879 hasConceptScore W4212868879C2779466945 @default.
• W4212868879 hasConceptScore W4212868879C2779929075 @default.
• W4212868879 hasConceptScore W4212868879C2780192828 @default.
• W4212868879 hasConceptScore W4212868879C44249647 @default.
• W4212868879 hasConceptScore W4212868879C71924100 @default.
• W4212868879 hasConceptScore W4212868879C74534348 @default.
• W4212868879 hasConceptScore W4212868879C95190672 @default.
• W4212868879 hasIssue "2" @default.
• W4212868879 hasLocation W42128688791 @default.
• W4212868879 hasLocation W42128688792 @default.
• W4212868879 hasLocation W42128688793 @default.
• W4212868879 hasOpenAccess W4212868879 @default.

• next